NEUROIMAGING AND NEURODEVELOPMENTAL OUTCOME: A SECONDARY TO SURFACTANT POSITIVE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 网络-医疗同意支持 I C.研究目的： 1)为了在入组SUPPORT的极早产儿中获得一致的、定时的和解释的神经影像学研究： a. 4-14日龄时的头颅US B. 35-42周PMA时的头颅US C. 35-42周PMA时的MRI 2)比较每个随机通气分层内低SpO 2组和高SpO 2组之间以及每个随机氧合分层内早期CPAP和对照通气组之间的早期和晚期US和MRI结果。 3)利用NICHD新生儿研究网络随访计划评估18-22个月矫正年龄时的神经发育结局，如支持中所述。 4)通过预测模型研究神经影像学结果与神经发育结局的独立相关性。 a.回归模型将评估早期和晚期头颅US和脑部MRI的绝对和相对值，单独和与传统风险因素结合，以预测18-22个月时的异常和正常神经发育结局。 B.通过逐步回归模型，评估 神经影像学发现，单独和组合，在预测神经发育的结果超过早期风险因素或早期和住院风险因素单独的价值。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Network - Antenatal Consent SUPPORT I C. Study Aim(s): 1) To obtain consistently performed, timed and interpreted neuroimaging studies in extremely preterm infants enrolled in SUPPORT: a. cranial US at 4-14 days of age b. cranial US at 35-42 weeks PMA c. MRI at 35-42 weeks PMA 2) To compare early and late US and MRI findings between Low and High SpO2 groups within each randomized ventilation strata, and between Early CPAP and Control ventilation groups within each randomized oxygenation strata. 3) To utilize the NICHD Neonatal Research Network follow-up programs to assess neurodevelopmental outcomes at 18-22 months corrected age, as described in SUPPORT. 4) To examine the independent associations of neuroimaging findings with neurodevelopmental outcomes through predictive modeling. a. Regression models will assess the absolute and relative value of early and late cranial US, and brain MRI, alone and in combination with traditional risk factors, to predict abnormal and normal neurodevelopmental outcome at 18-22 months. b. Through stepwise regression modeling, assess the value of neuroimaging findings, alone and in combination, in predicting neurodevelopmental outcomes over and above the value of early risk factors or early and in-hospital risk factors alone.